The concept has been around for more than a century, but recent advances in the field are causing numerous experts to say it’s widely underused. The goal of allergen immunotherapy (AIT) is to induce a specific immune tolerance by confronting patients with increasing levels of allergens. AIT developers are now working on improving efficacy and safety, while at the same time trying to speed up the still lengthy process of desensitisation. Peanuts in particular are in the crosshairs, as they cause one of the most life-threatening common allergies in humans.
Biocartis inks breast cancer R&D deal
Latest NewsBelgian diagnostics company Biocartis Group NV and Singpore’s A*STAR ETPL have kicked off development of a multimodal breast cancer assay designed to guide therapy selection in personalised medicine.
4SC AG raises €41m
Latest NewsSmall molecule cancer drug developer 4SC AG (Planegg-Martinsried, Germany) has completed a capital increase fueling development of its clinical programmes for resminostat, 4SC-202 and 4SC-208
Success for individualised cancer vaccine
Latest NewsGerman biotech company Biontech AG has published positive clinical results for its individualised cancer vaccine Ivac mutanome in patients with late-stage melanoma.
Seventure debuts in Japan with microbiome investment
Latest NewsVenture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventure’s Health for Life Capital investment vehicle.
Sygnis AG: Science and business rolled into one
AppointmentsGerman-Spanish biotech Sygnis AG has made changes to its management team and supervisory board. Heikki Lanckriet, who was previously Co-CEO, will become sole CEO of Sygnis and will also retain his role as Chief Scientific Officer.
Noxxon/MSD start testing of immunoncologic combo
Latest NewsLast December, Noxxon Pharma AG signed an agreement with Merck & Co./MSD to evaluate the synergistic potential of NOXA1/2 and pembrolizumab immune cancer therapy. Now, the companies have kicked off a Phase I/II study in patients with pancreatic and colorectal cancer.
ReadyTector Immunodetection
ProductsReadyTector is an easy, quick and clear all-in-one detection solution for Western blotting.
Allergies: Public Enemy Number One
BackgroundThe concept has been around for more than a century, but recent advances in the field are causing numerous experts to say it’s widely underused. The goal of allergen immunotherapy (AIT) is to induce a specific immune tolerance by confronting patients with increasing levels of allergens. AIT developers are now working on improving efficacy and safety, while at the same time trying to speed up the still lengthy process of desensitisation. Peanuts in particular are in the crosshairs, as they cause one of the most life-threatening common allergies in humans.
Exscientia inks €37m contract with GSK
Latest NewsBritish pharma giant GlaxoSmithKline has secured access to Ex Scientia Ltd (Exscientia)’s artificial intelligence (AI)-driven drug discovery platform.
Breaking therapy resistance of follicular lymphoma
Latest NewsSwiss researchers have found a way to prevent the multiple disease relapses after responses to follicular lymphoma therapy.